Since January 2019, patients have been able to track their progress at home via the IUCT-Oncopole’s web-based remote monitoring system. The new system, called Mon E-Suivi IUCT-Oncopole, not only ensures complications are detected as early as possible, it also encourages treatment compliance and helps reduce readmissions.
Mon E-Suivi IUCT-Oncopole covers seven treatment pathways:
- Outpatient surgery
- Cancer day hospital
- Clinical research day hospital
- Nutrition monitoring for radiotherapy
- COACH monitoring in medical oncology
- AMA monitoring in hematology
Mon E-Suivi IUCT-Oncopole connects patients with their healthcare team via a 100% secure online platform. Each treatment pathway is associated with a specific program covering all the different stages and criteria that require monitoring.
How it works
When you give your consent for home monitoring you will be assigned to one of the seven programs, according to your treatment pathway. You will then meet with a healthcare professional who will explain how the system works, the procedures to follow and how to login, etc. Back home, you will receive regular emails containing links to monitoring questionnaires you have to fill in on the website. An algorithm has been designed to analyze your answers to these questions. If the algorithm detects an anomaly, it will send alerts to your healthcare team, who will call you, and to your home. The alert you receive will include a hotline number you can call 24/7.
Additional features provided by the system include a personal diary showing forthcoming appointments, access to information and a messaging system for contacting the healthcare team.
Maximum patient safety guaranteed
- Remote monitoring is included in your patient file
- You receive specific information about your treatment pathway
- A 24/7 hotline is available in case of need
- Consent and data protection procedures meet current legislative requirements.
The Mon E-Suivi IUCT-Oncopole system was tested during 2017 with a sample of women who had received outpatient surgery for breast cancer. In a user-satisfaction survey carried out during this trial:
- 96% of women said they were happy with the system;
- 96% found it easy to use;
- 93% said it made them feel safer.
This positive feedback encouraged the IUCT-Oncopole to extend the system to other types of treatment.